// App-Quantinova.ai

O06 : Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials

Researchers

Presenter

  • David Walsh

Principal Investigators

  • Thomas J Schnitzer

  • Francis Berenbaum

  • Samantha Howland

  • Stefan Wilhelm

  • Rod Junor

Medical Centers

  • Pain Centre Versus Arthritis, NIHR Nottingham BRC and Academic Rheumatology, University of Nottingham, Nottingham, UNITED KINGDOM

  • Departments of Physical Medicine and Rehabilitation, Internal Medicine/Rheumatology, and Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL

  • Department of Rheumatology, Sorbonne Université, INSERM CRSA, AP-HP Hopital Saint Antoine, Paris, FRANCE

  • Pfizer Medical Affairs, Internal Medicine UK, Pfizer, Tadworth, UNITED KINGDOM

  • Lilly Medical Affairs, International Therapeutic Area Pain, Lilly Deutschland GmbH,, Bad Homburg, GERMANY

  • Global Product Development, Pfizer Ltd, Pfizer, Tadworth, UNITED KINGDOM

Locations

  • United Kingdom

  • United States

  • France

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT02709486

  • NCT02697773

Sponsors

  • Pfizer and Eli Lilly

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved